Welcome to our dedicated page for Longevity Health SEC filings (Ticker: XAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Longevity Health Holdings, Inc. (XAGE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, transaction documents, and listing-related notices. These filings offer detailed information on Longevity’s focus on human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, as well as its corporate and capital markets activities.
Among the key documents are Form 8-K current reports describing material events, such as merger agreements and amendments with 20/20 BioLabs, Inc. and True Health Inc. (THPlasma), and the subsequent termination of the merger agreement with True Health after the transaction was not consummated by the contractual outside date. These reports outline transaction structures, share consideration formulas, and the conditions required for closing.
Investors can also review a Form 25 filed by Nasdaq Stock Market LLC, which serves as a notification of removal of Longevity Health Holdings, Inc.’s common stock and warrants from listing and registration under Section 12(b) of the Securities Exchange Act of 1934 on the Nasdaq Stock Market. This filing documents the delisting process from Nasdaq.
Through Stock Titan, users can follow Longevity’s 10-K annual reports, 10-Q quarterly reports, and additional 8-Ks as they are filed with the U.S. Securities and Exchange Commission. AI-powered summaries help explain the significance of lengthy filings, highlight key risk factor updates, and surface important details in merger agreements, listing decisions, and financing disclosures. The page also makes it easier to monitor insider and executive-related filings, where available, and to understand how corporate actions affect the company’s structure and shareholders.
Longevity Health Holdings, Inc. files a prospectus supplement registering 44,382 shares of Common Stock as an amendment to its Form S-1 prospectus dated June 5, 2024. The supplement incorporates the Company’s Form 10-K for the fiscal year ended December 31, 2025 and attaches an 8-K.
The Company trades on the OTC market under symbol XAGE; the last reported sale price was $0.39 per share on March 30, 2026. The Form 10-K discloses a closed PIPE on March 16, 2026 raising $200,000 from the sale of 689,656 shares at $0.29 per share, a CEO transition with severance payments of $30,000 per month for 12 months (with conditional extension), and management’s conclusion that substantial doubt exists about the Company’s ability to continue as a going concern.
Longevity Health Holdings, Inc. is a microcap aesthetics company focused on regenerative bio-aesthetic skincare and haircare under the Elevai and Carmell brands, using exosome- and platelet-rich plasma-based formulations sold through physicians, medical spas, distributors, and online channels. The company has paused development of its bone and tissue healing candidates to focus on cosmetics.
In March 2026, it completed a private placement of 689,656 common shares at $0.29 for approximately $200,000 with International Capital Partners LLC and simultaneously transitioned leadership, with former Chairman and CEO Rajiv Shukla departing and Janakiram Ajjarapu becoming Chairman and CEO. Shukla receives $30,000 per month for 12 months, with potential extensions and a contingent $480,000 bonus payment tied to a larger capital raise.
As of June 30, 2025, non-affiliate common stock held a market value of about $3.3 million, and 2,475,321 shares were outstanding as of March 27, 2026. The filing highlights substantial competition in the cosmetics industry, reliance on third-party manufacturing and human-tissue-derived inputs, and significant regulatory exposure, including new obligations under the Modernization of Cosmetic Regulation Act of 2022. Management discloses that substantial additional capital will be needed and acknowledges a conclusion that there is substantial doubt about the company’s ability to continue as a going concern.
Longevity Health Holdings entered into a Common Stock Purchase Agreement with International Capital Partners LLC, selling 689,656 shares of common stock at $0.29 per share for aggregate proceeds of approximately $200,000 in a private placement that closed on March 16, 2026.
In connection with the investment, the Board appointed Janakiram (Ram) Ajjarapu as Chairman and Chief Executive Officer, replacing Rajiv S. Shukla, who stepped down under a mutual agreement and will serve as an advisor. The company plans to register the resale of the purchased shares through a future registration statement.
Under a Separation Agreement, Mr. Shukla will receive $30,000 per month for 12 months, potentially extended to 18 months upon a qualifying change in control, and a $480,000 bonus if the company completes a capital raise of at least $1 million, while his existing equity awards are forfeited.
Longevity Health Holdings, Inc. has terminated its planned acquisition of True Health Inc. and Truehealth Management Group LLC. The companies had entered into a Merger Agreement on July 14, 2025, later amended on November 3, 2025, under which True Health would have become a wholly owned subsidiary of Longevity Health.
Under a provision in the agreement allowing either side to walk away if the deal was not closed by November 30, 2025, Longevity Health delivered a formal termination notice on December 8, 2025 after the merger was not completed by the deadline. No termination fee is payable by either party in connection with ending the agreement, so neither side owes a contractual breakup payment.
Longevity Health Holdings, Inc. has had its common stock and warrants removed from listing and/or registration on the Nasdaq Stock Market LLC, as reflected in a Form 25 notification filed by the exchange. The filing states that Nasdaq has complied with its rules to strike these classes of securities from listing and withdraw their registration under Section 12(b) of the Securities Exchange Act of 1934.
This action means the company’s securities will no longer trade on Nasdaq, which can affect trading visibility and access for many investors. The notification is signed on behalf of Nasdaq by a hearings advisor, confirming the exchange’s belief that it meets all requirements for filing Form 25.
Longevity Health Holdings (XAGE) filed its Q3 2025 10‑Q, reporting higher sales but ongoing losses and liquidity pressure. Net sales were $425,864, up sharply from $20,519 a year ago; nine‑month net sales reached $1,439,829. The company posted a Q3 net loss of $1,429,755 and a nine‑month loss of $4,822,060.
Cash rose to $1,109,228 from $157,139 at year‑end, aided by $4,139,212 of financing inflows, including a January private placement and a May at‑the‑market program, plus $1,000,000 of warrant exercises. Operating cash use was $3,022,899 for the nine months. Management disclosed substantial doubt about the ability to continue as a going concern, citing a working capital deficit of $3,997,047.
The company completed the Elevai asset acquisition in January, recording $660,805 of stock consideration and potential earnouts, and effected a 1‑for‑30 reverse stock split in May. As of November 12, 2025, common shares outstanding were 1,781,738. A merger agreement with THPlasma includes equity consideration mechanics and closing conditions, with no timing commitments stated here.
Longevity Health Holdings (XAGE) amended its merger agreement with True Health. The revision sets how stock consideration will be calculated. The Merger Shares will equal $59,000,000 divided by the lesser of the “Parent Market Price” and $3.00. The Earnout Shares will equal $20,000,000 divided by the lesser of the Parent Market Price and $3.00. Parent Market Price is defined as the volume average weighted closing sale price over the 15 consecutive full trading days immediately before the merger’s effective time.
As outlined previously, upon closing, True Health would become a wholly owned subsidiary and the company would acquire specified FDA authorizations from Truehealth Management Group LLC. The filing reiterates customary risks, including required regulatory approvals, satisfaction of closing conditions, potential Nasdaq listing considerations for the combined company, integration execution, and market price variability relative to the Parent Market Price.